Drugs that contain Omaveloxolone

1. List of Skyclarys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9670147 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Apr, 2029

(5 years from now)

US8124799 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Dec, 2029

(6 years from now)

US8993640 REATA PHARMS 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(9 years from now)

US9701709 REATA PHARMS 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440854 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17
Apr, 2029

(5 years from now)

US11091430 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
Apr, 2029

(5 years from now)

Do you want to check out SKYCLARYS patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 28, 2030
New Chemical Entity Exclusivity (NCE) Feb 28, 2028

NCE-1 date: 2027-02-28

Market Authorisation Date: 28 February, 2023

Treatment: Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older

Dosage: CAPSULE;ORAL

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic